EC
TYRA icon

EntryPoint Capital’s Tyra Biosciences TYRA Stock Holding History

EntryPoint Capital’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,892
Closed -$138K – 825
2025
Q1 		$138K Sell
14,892
-3,317
-18% -$42.9K 0.06% 596
2024
Q4 		$253K Buy
+18,209
New +$330K 0.11% 471
2024
Q2 		– Sell
-1,345
Closed -$22.1K – 1630
2024
Q1 		$22.1K Buy
+1,345
New +$22.1K 0.02% 1065

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

EntryPoint Capital's TYRA Position: Q2 2025 in Review

EntryPoint Capital sold out of Tyra Biosciences (TYRA) in Q2 2025, closing a stake of 14,892 shares — an estimated $138K sold.

EntryPoint Capital first reported a position in TYRA in Q1 2024 and held it in 3 quarters. The position peaked at $253K in Q4 2024. 121 funds tracked by Wall St. Rank hold TYRA as of Q2 2025.

  • EntryPoint Capital reported no remaining Tyra Biosciences position as of Q2 2025 after selling out during the quarter.
  • EntryPoint Capital sold 14,892 Tyra Biosciences shares in Q2 2025, an estimated $138K.
  • EntryPoint Capital first reported a position in Tyra Biosciences in Q1 2024 and held it in 3 quarters.
  • EntryPoint Capital's Tyra Biosciences position peaked at $253K in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.